Possible relationship between dietary factors and pathogenesis of prostate cancer

International Journal of Urology

Volumn 5, Issue 3, 1998, Pages 195-213

  Griffiths, Keith ^a   Denis, Louis ^b   Turkes, Arilla ^a   Morton, Michael S ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b Oncology Centre of Antwerp   (Belgium)

Author keywords

Cancer; Diet; Growth factors; Hormones; Prostate; Review

Indexed keywords

ANDROGEN; AROMATASE; DNA TOPOISOMERASE; ESTROGEN; PROTEIN TYROSINE KINASE; STEROID 5ALPHA REDUCTASE;

ANGIOGENESIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; DIET; ENZYME INHIBITION; EPITHELIUM CELL; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STROMA CELL;

EID: 0031838195     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00591.x     Document Type: Review

References (182)

1. Griffiths K, Cockett ATK, Coffey DS, Krieg M, Lee C, McKeehan W, Neal DE, Partin A, Di Sant'Agnese A, Schalken J. Regulation of prostate growth. In: Denis L, Cockett ATK, Chatelaine C, Griffiths K, Khoury S, Murphy G (eds) The 4th international consultation on benignprostatic hyperplasia. Paris: SCI, 1998 (in press).
2. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin N Am 1995;22: 247-261.
3. Griffiths K, Coffey D, Cockett ATK, Di Sant'Agnese A, Ichikawa T, Krieg M, Lee C, McKeehan W, Schalken J, Sciarra F, Steiner G, Sugimura Y, Yamanaka H. The regulation of prostatic growth. In: Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds) The 3rd international consultation on benign prostatic hyperplasia. Paris: SCI, 1996:73-115.
4. Franks LM. Benign nodular hyperplasia of the prostate: a review. Ann R Coll Surg England 1954;14:92-106.
5. Barry MJ, Boyle P, Fourcroy J, Garraway M, Gu FL, Harrison NW, Jacobsen SJ, O'Leary MP, Oishi K, Senge T, Tsukamoto T, Guess HA. Epidemiology and natural history of BPH. In: Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds) The 3rd international consultation on benign prostatic hyperplasia. Paris: SCI, 1996:21-36.
6. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-471.
7. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
8. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989;14:(suppl 2):33-50.
9. Bruchovsky N, Lesser B, Van Doorn E, Craven S. Hormonal effects on cell proliferation in rat prostate. Vitam Horm 1975;33:61-102.
10. Truss M, Beato M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 1993;14:459-479.
11. Gronemeyer H. Transcription activation by estrogen and progesterone receptors. Ann Rev Genet 1991;25: 89-123.
12. Imperato-McGinley J, Guerro L, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974;186:1213-1215.
13. Griffiths K, Akaza H, Eaton CL, El Etreby M, Habib F, Lee C, Partin AW, Coffey DS, Sciarra F, Steiner G, Tenniswood MP. Regulation of prostate growth. In: Cockett ATK, Khoury S, Aso Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds) The 2nd international consultation on benign prostatic hyperplasia. Paris: SCI, 1993:49-75.
14. Lee C, Kozlowski JM, Grayhack JT. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate 1997;31:131-138.
15. Franks LM, Riddle PN, Carbonell AW, Gey GO. A comparative study of the ultrastructure and lack of growth capacity of adult human prostate epithelium mechanically separated from its stroma. J Pathol 1970;100:113-119.
16. Cunha GR, Chung LWK, Shannon JM, Taguchi O, Fujii H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Rec Prog Horm Res 1983;39:559-595.
17. Chung LWK, Cunha GR. Stromal-epithelial interactions. II. Regulation of prostatic growth by embryonic urogenital sinus mesenchyme. Prostate 1983;4:503-511.
18. Yan G, Fukabori Y, Nikoloropolous S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 1992;6:2123-2128.
19. Peehl DM, Wong ST, Rubin JS. KGF and EGF differentially regulate the phenotype of prostatic epithelial cells. Growth Regul 1996;6:22-31.
20. Sugimura Y, Foster BA, Hom YK, Lipschutz JH, Rubin JS, Finch PW, Aaronson SA, Hayashi N, Kawamura J, Cunha GR. Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Develop Biol 1996;40: 941-951.
21. Culig Z, Hobixch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor I, keratinocyte growth factor and epidermal growth factor. Cancer Res 1994;54:5474-5478.
22. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AML, Aaronson SA. Determination of ligand-binding specificity by alternate splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci 1992;89:246-250.
23. Sherwood ER, Fong CJ, Lee C, Kozlowski JM. Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Endocrinology 1992;130: 2955-2963.
24. Leung HY, Dickson C, Robson CN, Neal DE. Over-expression of fibroblast growth factor-8 in human prostate cancer. Oncogene 1996;12:1833-1835.
25. Schmitt JF, Hearn MT, Risbridger GP. Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells. J Steroid Biochem Mol Biol 1996;57:173-178.
26. Yan G, Fukabori Y, McBride G, Nikolarapolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-4522.
27. MacArthur CA, Lawshe A, Xu A, Santos-Ocampo S, Heikinheimo M, Chellaiah AT, Ornitz DM. FGF-8 isoforms activate receptor splice variants that are expressed in mesenchymal regions of mouse development. Development 1995;121:3603-3613.
28. Krieg M, Bartsch W, Thomsen M, Voigt KD. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. J Steroid Biochem 1983;19:155-161.
29. Habenicht UF, El Etreby MF. Selective inhibition of androstenedione-induced prostate growth in intact beagle dogs by a combined treatment with the antiandrogen cyproterone acetate and the aromatase inhibitor 1-methylandrostan-1,4-diene-3,17-dione. Prostate 1989; 14:309-322.
30. Ittman M, Mansukhani A. Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate. J Urol 1997;157:351-356.
31. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci 1996;93:5925-5930.
32. Mosselman S, Polman J, Dijkema R. ERβ: identification and characterization of a novel human estrogen receptor. FEBS Letters 1996;392:49-53.
33. Kuiper GGJM, Carlsson B, Grandien J, Enmark E, Haggblad J, Nilsson S, Gustafson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997;138:863-870.
34. Berry M, Metzger D, Chambon P. Role of the two activating domains of estrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-estrogen 4-hydroxytamoxifen. EMBO J 1990;9: 2811-2818.
35. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP. Human estrogen receptor transactivational capacity is determined by both cellular and promoter-content and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994;8:21-30.
36. Kraus WL, Mclnerny EM, Katzenellenbogen BS. Ligand-dependent, transcriptionally productive association of the amino- and carboxy-terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci 1995;92: 12314-12318.
37. Montano MM, Muller V, Trobaugh A, Katzenellenbogen BS. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 1995;9:814-825.
38. Katzenellenbogen JA, O'Malley BW, Katzenellenbogen BS. Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a base for the cell- and promoter-specific action of these hormones. Mol Endocrinol 1996;10:119-131.
39. Lee C, Sensibar JA, Dudek SM, Hiipakka RA, Liao S. Prostatic ductal system in rats: regional variation in morphological and functional activities. Biol Reprod 1990; 43:1079-1086.
40. Sensibar JA, Griswold MD, Sylvester SR, Buttyan R, Bardin CW, Cheng CY, Dudek S, Lee C. Prostatic ductal system in rats: regional variation in localization of an androgen-repressed gene product, sulfated glycoprotein-2. Endocrinology 1991;128:2091-2102.
41. Wong P, Pineault J, Lakins JN, Taillefer D, Leger J, Wang C, Tenniswood MP. Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J Biol Chem 1993;268:5021-5031.
42. Rouleau M, Leger J, Tenniswood MP. Ductal heterogeneity of cytokeratins, gene expression and cell death in the rat ventral prostate. Mol Endocrinol 1990;4:2003-2013.
43. Kyprianou N, Isaacs JT. Expression of transforming growth factors in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 1989;3:1515-1522.
44. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984;5:545-557.
45. Ichihara I, Kallio M, Pelliniemi LJ. Light and electron microscopy of the ducts and their sub-epithelial tissue in the rat ventral prostate. Cell Tissue Res 1978;192: 381-390.
46. Nemeth JA, Lee C.The prostatic ductal system in rats: regional variation in stromal organization. Prostate 1996;28:124-128.
47. Cooke PS, Young P, Cunha GR. Androgen receptor expression in developing male reproductive organs. Endocrinology 1991;128:2867-2873.
48. Cooke PS, Young P, Hess RA, Cunha GR. Estrogen receptor expression in developing epididymis, efferent ductules and other male reproductive tissues. Endocrinology 1991;128:2874-2879.
49. Toney TW, Danzo BJ. Developmental changes in and hormonal regulation of estrogen and androgen receptors present in the rabbit epididymis. Biol Reprod 1988;39:818-828.
50. Toney TW, Danzo BJ. Androgen and estrogen effects on protein synthesis by the adult rabbit epididymis. Endocrinology 1989;125:243-249.
51. Di Sant Agnese P. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 1992;70:254-268.
52. Larsson LI. On the possible existence of multiple endocrine, paracrine and neuroendocrine messengers in secretory cell systems. Invest Cell Pathol 1980;3:73-85.
53. Bishop A, Polak J. Gut endocrine and neural peptides. Endocr Pathol 1990;1:1-24.
54. Cockett ATK, Di Sant Agnese PA, Gopinath P, Schoen SR, Abrahamsson PA. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 1993;42:512-519.
55. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-1720.
56. Aprikian A, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in hu-man prostate cancer cells. J Mol Endocrinol 1996;16: 297-306.
57. Wasilenko A, Cooper J, Palad A, Somers K, Blackmore P, Rhim J, Wright G, Schelhammer P. Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate 1997; 30:167-173.
58. Han K, Viallet J, Chevalier S, Zheng W, Bazinet M, Aprikian A. Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells. Prostate 1997;31:53-60.
59. Ritchie C, Thomas K, Andrews L, Tindall D, Fitzpatrick L. Effects of the calciotropic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 1997;30:183-187.
60. Iwamura M, Wu G, Abrahamsson PA, Cockett ATK, Foss K, Deftos L. Parathyroid hormone-related protein: a potential autocrine growth regulator in human prostate cancer cell lines. Urology 1994;43:675-679.
61. Abdul M, Anezinis P, Logothetis C, Hoosein N. Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. Anticancer Res 1994;14:1215-1220.
62. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor VEGF expression in prostatic tumors and its relationship to neuroendocrine cells. Br J Cancer 1996;74:910-916.
63. Griffiths K, Morton MS, Nicholson RI. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Eur Urol 1997;32(suppl 3):24-40.
64. Isaacs JT, Cussenot O, Jankevicius F, Klocker H, Kubota Y, Morgia G, Rennie P, Schmitz-Drager BJ. Growth regulation of normal and malignant prostatic cells. In: Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett AT (eds) First international consultation on prostate cancer. Paris: SCI, 1996;31-81.
65. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
66. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-447.
67. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
68. Bang Y, Pirnia F, Fang W, Kang W, Sartor O, Whitesell L. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci 1994;91:5330-5334.
69. Segal N, Cohen R, Huffejee Z, Savage N. Bcl-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994;118:616-618.
70. Seuwen K, Poiyssegur J. Serotonin as a growth factor. Biochem Pharmacol 1990;39:985-990.
71. Kinghorn EM, Bate AS, Higgins SJ. Growth of rat seminal vesicle epithelial cells in culture: neurotransmitters are required for androgen-regulated synthesis of tissue-specific secretory proteins. Endocrinology 1987;121: 1678-1688.
72. Tutton BJ, Barkla DH. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells. Anticancer Res 1987;7:1-12.
73. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci 1986;83:674-678.
74. Seuwen K, Magnaldo I, Pouyssegue J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to G-protein. Nature 1988;335: 254-256.
75. Cockett ATK, Di Sant'Agnese PA, Gopinath P, Schoen S, Abrahamsson PA. Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Adult Urol 1993;42:512-519.
76. Power RF, Mani SK, Codina J, Conneely OM, O'Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991; 254:1636-1639.
77. Verhagen APM, Aalders TW, Ramaekers FCS, Debruyne FM, Schalken JA. Differential expression of keratins in the basal and luminal compartments of rat prostate epithelium during degeneration and regeneration. Prostate 1988;13:25-38.
78. Isaacs JT. Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In: Rodgers CH, Coffey DS, Cunha GR, Grayhack JT, Hinman F, Horton R (eds) Benign prostatic hyperplasia. NIH Publication No. 87-2881. Bethesda, MD: National Institutes of Health 1988;2:85-94.
79. Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994;25: 42-46.
80. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
81. Denmeade SR, Lin SX, Isaacs JT. The role of programmed apoptotic cell death during the progression and therapy for prostate cancer. Prostate 1995;28:251-265.
82. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancers. Am J Pathol 1993;143:390-400.
83. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
84. McDonnell ML, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hseih J, Tu S, Campbell ML. Expression of the proto-oncogene bcl-2 in prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
85. Aaronson S. Growth factors and cancer. Science 1991; 254:1146-1153.
86. Weinberg RA.The action of oncogenes in the cytoplasm and nucleus. Science 1983;230:770-776.
87. Curran T, Bravo R, Muller R.Transient induction of c-fos and c-myc is an intermediate consequence of growth factor stimulation. Cancer Surv 1985;4:655-681.
88. Jones N.Transcriptional regulation by dimerization: two sides to an incestuous relationship. Cell 1990;61:9-11.
89. Landschultz, WH, Johnson PF, McKnight SL. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 1986;240:1759-1764.
90. Schule R, Muller M, Kaltschmidt C, Rentawitz R. Many transcription factors interact synergistically with steroid receptors Science 1988;242:1418-1420.
91. Shemshedini L, Knauthe R, Sassone-Corsi P, Pornon A, Gronemeyer H. Cell specific inhibitory and stimulatory effects of fos and jun on transcription activation by nuclear receptors. EMBO J 1991;10:3839-3849.
92. Sabbah M, Le Recousse S, Redeuilh G, Beaulieu EE. Estrogen receptor-induced binding of the xenopus vitellogenin A2 gene hormone response element. Biochem Biophys Res Commun 1992;185:944-952.
93. Nardulli AM, Shapiro DJ. Binding of the estrogen receptor DNA-binding domain to the estrogen response element induces DNA binding. MoL Cell Biol 1992;12: 2037-2042.
94. Chodak GW, Krane DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992;147:798-803.
95. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995;83:851-857.
96. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-850.
97. Saatcioglu F, Claret FX, Karin M. Negative transcriptional regulation by nuclear receptors. Semin Cancer Biol 1994;5:347-359.
98. Xue Y, Schalken JA, Miller GJ, Ruijter ET, Aalders TW, Debruyne FMJ. Immunohistochemical determination of in vivo distribution of branching patterns in human adult prostate. J Urol 1996;155:332A.
99. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1006;27:683-687.
100. Timms BG, Mohs TJ, Didio LJA. Ductal budding and branching patterns in the developing prostate. J Urol 1994;151:1427-1432.
101. Sugimura Y, Norman JT, Cunha GR, Shannon JM. Regional differences in the inductive activity of the mesenchyme of the embryonic mouse urogenital sinus. Prostate 1985;7:253-260.
102. Santti R, Newbold RR, Makela S, Pylkkanen L, McLachlan JA. Developmental estrogenization and prostatic neoplasia. Prostate 1994;24:67-78.
103. Vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, Dhar MD, Ganjam VK, Parmigiani S, Welshons WV. Prostate enlargement in mice due to fetal exposure to a low dose of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci 1997;94:2056-2061.
104. Nakhla AM, Khan MS, Romas NP, Rosner W. Estradiol causes the rapid accumulation of cAMP in human prostate. Proc Natl Acad Sci 1994;91:5402-5405.
105. Suarez-Pinzon WL, Strynadka K, Schulz R, Rabinovitch A. Mechanisms of cytokine-induced destruction of rat insulinoma cells: the role of nitric oxide. Endocrinology 1994;134:1006-1010.
106. Kyprianou N, Litvak JP, Alexander RB, Borkowski A, Jacobs SC. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Clin Invest 1998 (in press).
107. Sarafian TA, Bredesen DE. Is apoptosis mediated by reactive oxygen species? Free RadiC Res 1994;20:1-6.
108. Griffiths K, Adlercreutz H, Boyle P, Denis L, Nicholson RI, Morton M. Nutrition and Cancer. Oxford: Isis Medical Media, 1996.
109. Haenzel W, Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968,40:43-68.
110. Shimizu H, Ropp RK, Bernstein L, Yatani R, Henderson BE, Mack TH. Cancers of the breast and prostate among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-966.
111. Bradbury RB, White DC. Estrogens and related substances in plants. Vitam Horm 1954;12:207-233.
112. Price KR, Fenwick GR. Naturally occurring estrogens in food-a review. Food Add Contam 1985;2:73-106.
113. Verdeal K, Brown RR, RichardsonT, Ryan DS. Affinity of phytestrogens for estradiol-binding proteins and effect of coumestrol on growth of 7,12-dimethylbenza anthracene-induced rat mammary tumors. J Natl Cancer Inst 1984;64:285-290.
114. Axelson M, Sjovall J, Gustafsson BE, Setchell KDR. A dietary source of the non-steroidal estrogen equol in man and animals. J Endocrinol 1984;102:49-56.
115. Setchell KDR, Adlercreutz H. Mammalian lignans and phytoestrogens. Recent studies on their formation, metabolism and biological role in health and disease. In: Rowland IR (ed) Role of gut flora in toxicity and cancer. London: Academic Press, 1988:315-345.
116. Walz E. Isoflavon und sapogenin-glucoside in sojahispida. Justus Liebigs Annal Chem 1931;489:118-155.
117. Coward L, Barnes NC, Setchell KDR, Barnes S. Genistein, daidzein, and their β-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem 1993;41:1961-1967.
118. Rosenblum ER, Campbell IM, VanThiel DH, Gavaler JS. Isolation and identification of phytestrogens from beer. Alcohol Clin Exp Res 1992;16:843-845.
119. Van Thiel DH, Galvao-Teles A, Monteiro E, Rosenblum E, Gavaler JS. The phytestrogens present in deethanolized bourbon are biologically active: a preliminary study in postmenopausal women. Alcohol Clin Exp Res 1991;15:822-823.
120. Rao CBS (ed) The Chemistry of Lignans. Waltair, India: Andra University Press and Publications, 1978:1-377.
121. Thompson LU, Robb P, Serraino M, Cheung F. Mammalian lignan production from various foods. Nutr Cancer 1991;16:43-52.
122. Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993;44:37-43.
123. Kelly GE, Nelson C, Waring MA, Joannou GE, Reeder AY. Metabolites of dietary soya isoflavones in human urine. Clin Chim Acta 1993;223:9-22.
124. Adlercreutz H, Fotsis T, Bannwart C, Wahala K, Makela T, Brunow G, Hase T. Determination of urinary lignans and phytestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 1986;25:791-797.
125. Morton MS, Wilcox G, Wahlquvist ML, Griffiths K. Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. J Endocrinol 1994;142:251-259.
126. Finlay EMH, Wilson DW, Adlercreutz H, Griffiths K. The identification and measurement of "phyto-estrogens" in human saliva, plasma, breast aspirate or cyst fluid, and prostatic fluid using gas chromatography-mass spectrometry. J Endocrinol 1991;129(suppl):49.
127. Dehennin L, Reiffsteck A, Joudet M, Thibier M. Identification and quantitative estimation of a lignan in human and bovine semen. J Reprod Fert 1982;66:305-309.
128. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, Okada H. Urinary excretion of lignans and isoflavonoid phytestrogens in Japanese men and women consuming traditional Japanese diet. Am J Clin Nutr 1991;54:1093-1100.
129. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-estrogens in Japanese men. Lancet 1993;342:1209-1210.
130. Setchell KDR, Borriello SP, Hulme P, Kirk DN, Axelson M. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 1984;40:569-578.
131. Pope GS, Wright HG. Estrogenic isoflavones in red clover and subterranean clover. Chem Ind 1954;17:1019-1020.
132. Bickoff EM. Estrogen-like substances in plants. In: Hissaw FL (ed) Physiology of reproduction. Proceedings of the 22nd Animal Biology Colloquium. Corvallis: Oregon State University Press, 1982:93-118.
133. Waters AP, Knowler JT. Effect of a lignan HPMF on RNA synthesis in the rat uterus. J Reprod Fert 1982;66: 379-381.
134. Martin PM, Horwitz KB, Ryan DS, McGuire WL. Phytestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinology 1978;103: 1860-1867.
135. Adlercreutz H, Hockerstedt K, Bannwart C, Bloigu S, Hamalainen E, Fotsis T, Ollus A. Effect of dietary components, including lignans and phytestrogens on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin SHBG. J Steroid Biochem 1987;27:1135-1144.
136. Kuiper GG, Carlson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity of transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-870.
137. Cunha GR, Chung LWK, Shannon JM, Taguchi O, Fujii H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interaction. Rec Prog Horm Res 1983;39:559-595.
138. Griffiths K, Davies P, Eaton CL, Harper ME, Turkes A, Peeling WB. Endocrine factors in the initiation, diagnosis and treatment of prostatic cancer. In: Voigt K-D, Knabbe C (eds) Endocrine dependent tumors. New York: Raven Press, 1991:83-130.
139. Coffey DS. Physiologie de la prostate. In: Khour S, Chatelain C (eds) Urologie, cancer de la prostate. Paris: FUS Publications, 1988:70-103.
140. Griffiths K, Davies P, Eaton CL, Harper ME, Peeling WB, Turkes AO, Turkes A, Wilson DW, Pierrepoint CG. Cancer of the prostate: endocrine factors. In: Clark JR (ed) Oxford reviews of reproductive biology. Oxford: Clarendon Press, 1987;9:192-259.
141. Vermeulen A, Rubens R, Verdonck L. Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab 1972;34:730-735.
142. Rubens R, Dhont M, Vermeulen A. Further studies on Leydig cell function in old age. J Clin Endocrinol Metab 1974;39:40-45.
143. Vermeulen A, van Camp A, Mattelaer J, De Sy W. Hormonal factors related to abnormal growth of the prostate. In: Coffey DS, Isaacs JT (eds) Prostate cancer. Geneva: UICC Technical Workshop Series, 1979;48: 81-92.
144. Belanger A, Locong A, Noel C, Cusan L, Dupont A, Prevost J, Caron S, Sevigny J. Influence of diet on plasma steroids and sex hormone-binding globulin levels in adult men. J Steroid Biochem 1989;32:829-833.
145. Vermeulen A. Metabolic effects of obesity in men. Verhandelingen-Koninklijke Academie Geneeskunde Belgie 1993;55:393-397.
146. Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol 1993;150:1736-1739.
147. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-alpha-androstan-l 7-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968;243:2012-2021.
148. Bruchovsky N, Wilson JD.The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem 1968;243:5953-5960.
149. Anderson KH, Liao S. Selective retention of dihydrotestosterone by prostatic nuclei. Nature London 1968; 219:277-279.
150. Evans BAJ, Griffiths K, Morton M. Inhibition of 5-reductase and 17β-hydroxysteroid dehydrogenase in genital skin fibroblasts by dietary lignans and isoflavonoids. J Endocrinol 1995;147:295-302.
151. Ross RK, Bernstein L, Lobo RA, Shimuzu H, Stanczyk FZ, Pike MC, Henderson BE. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992;339:887-889.
152. Rittmaster RS. Finasteride. New Engl J Med 1994;330: 120-125.
153. Vermeulen A. Testicular hormone secretion and aging in males. In: Grayshack JT, Wilson JD, Saherbenske MJ (eds) Benign prostatic hyperplasia. DHEW Publication No. NIH 76-1113. Bethesda: National Institutes of Health, 1976:177-182.
154. Vermeulen A, Deslypere JP, Meirleir K. A new look to the andropause: altered function of the gonadotrophs. J Steroid Biochem 1989;32:163-165.
155. Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, Hase T, Arosemena PJ, Kellis JT, Vickery LE. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytestrogens. J Steroid Biochem Mol Biol 1993;44:147-153.
156. Hunter T, Cooper JA. Protein tyrosine kinases. Ann Review Biochem 1985;54:897-930.
157. Bishop JM. Cellular oncogenes and retroviruses. Ann Review Biochem 1985;52:301-354.
158. Schlessinger J, Schreiber AB, Levi A, Lax J, Liberman T, Yarder Y. Regulation of cell proliferation by epidermal growth factor. Crit Rev Biochem 1983;14:93-111.
159. Kenyon GL, Garcia GA. Design of kinase inhibitors. Med Res Rev 1987;7:389-416.
160. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanaba S-I, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5595.
161. Kuo ML, Lin JK, Huang TS, Yang NC. Reversion of the transformed phenotypes of v-H-ras NIH3T3 cells by flavonoids through attenuating the content of phosphotyrosine. Cancer Lett 1994;87:91-97.
162. Kiguchi K, Glesne D, Chubb CH, Fujiki H, Huberman E. Differential induction of apoptosis in human breast cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Cell Growth Differ 1994;5:995-1004.
163. Scholar EM, Toews ML. Inhibition of invasion of murine mammary carcinoma cells by the tyrosine kinase inhibitor genistein. Cancer Lett 1994;87:159-162.
164. Tiisala S, Majuri ML, Carpen O, Renkonen R. Genistein enhances the ICAM-mediated adhesion by inducing the expression of ICAM-1 and its counter receptors. Biochem Biophys Res Commun 1994;203: 443-449.
165. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 1993;4:533-543.
166. McCabe MJ Jr, Orrenius S, Genistein induces apoptosis in immature human thymocytes by inhibiting topoisomerase-II. Biochem Biophys Res Commun 1993;194: 944-950.
167. Constantinou A, Mehta R, Runyan C, Rao K, Vaughan A, Moon R. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships. J Natl Prod 1995;58:217-225.
168. Spinozzi F, Pagliacci MC, Migliorati G, Moraca R, Grignani F, Riccardi C, Nicoletti I. The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. Leuk Res 1994;18:431-439.
169. Matsukawa Y, Marui N, Sakai T, Satomi Y, Yoshida M, Matsumoto K, Nishino H, Aoike A. Genistein arrests cell cycle progression at G2-M. Cancer Res 1993;53: 1328-1331.
170. Sato F, Matsukawa Y, Matsumoto K, Nishino H, Sakai T. Apigenin induces morphological differentiation and G-2M arrest in rat neuronal cells. Biochem Biophys Res Commun 1994;204:578-584.
171. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989,339:58-61.
172. Folkman J. Toward an understanding of angiogenesis: search and discovery. Perspect Biol Med 1985;29:10-36.
173. Weidner M, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metaplasia-correlation in invasive breast cancer. New Engl J Med 1991;324:1-8.
174. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci 1993;90:2690-2694.
175. Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radical Res 1995;22:375-383.
176. Mangiapane H, Thomson J, Salter A, Brown S, Bell GD, White DA. The inhibition of the oxidation of low density lipoprotein by (+)-catechin, a naturally occurring flavonoid. Biochem Pharmacol 1992;43:445-450.
177. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer. 1994;21:113-130.
178. Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistant gene. Biochem Biophys Res Commun 1991;179: 661-667.
179. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993;22:335-345.
180. Chae YH, Ho DK, Cassady JM, Cook VM, Marcus CB, Baird WM. Effects of synthetic and naturally occurring flavonoids on metabolic activation of benzopyrene in hamstercell cultures. Chem Biol Intern 1992;82:181-193.
181. Shi ST, Wang ZY, Smith TJ, Hong JY, Chen WF, Ho CT, Yang CS. Effects of green tea and black tea on 4-methylnitrosoamino-1-3-pyridyl-1-butanone bioactivation, DNA methylation and lung tumorigenesis in A/J mice. Cancer Res 1994;54:4641-4647.
182. Adlercreutz H, Hamalainen E, Gorbach S, Goldin B. Dietary phyto-estrogens and menopause in Japan. Lancet 1992;339:1233.